Placeholder Banner

BIO Comments on Draft Guidance: Q13 Continuous Manufacturing of Drug Substances and Drug Products

December 13, 2021

On Monday, December 13th, BIO submitted comments to the Food and Drug Administration’s recent draft guidance for industry entitled, Q13 Continuous Manufacturing of Drug Substances and Drug Products. The draft guidance was prepared under the auspices of the International Council for Harmonisation (ICH) and provides clarification on continuous manufacturing (CM) concepts and describes scientific approaches and regulatory considerations specific to CM of drug substances and drug products. According to the Agency, the draft guidance is intended to provide scientific and regulatory considerations for the development, implementation, operation, and lifecycle management of CM. In the comments submitted, BIO recommended the inclusion of additional terms in the guidance’s glossary, offered suggestions of where it might be helpful for the Agency to include specific examples, and requested the revision or addition of language to further clarify a handful of key points.

Download Full Comments Below
BIO Comments on Draft Guidance: Q13 Continuous Manufacturing of Drug Substances and Drug Products
Discover More
On Monday, May 9th, BIO submitted comments in response to the FDA’s recent draft guidance on Clinical Pharmacology Considerations for Antibody-Drug Conjugates. In the comments submitted, BIO acknowledged the challenge FDA faces in creating a…
We are writing on behalf of the Biotechnology Innovation Organization (BIO) to provide comments on the Federal Trade Commission’s (FTC’s or the Commission’s) Solicitation for Public Comments on the Business Practices of Pharmacy Benefit Managers and…
On Wednesday, April 27th, BIO submitted comments regarding an upcoming meeting of ODAC’s Pediatric Oncology Subcommittee on PREA Waivers for Same-in-Class Drugs. In particular, the subcommittee will meet to discuss the development of a conceptual…